Your session is about to expire
← Back to Search
This trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
- Idiopathic Pulmonary Fibrosis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you please detail the safety profile of BMS-986278 Dose 1?
"Based on the available data, our team at Power has assessed BMS-986278 Dose 1's safety to be 3 out of a possible score range from 1 to 3. This score is due to multiple rounds of clinical testing demonstrating efficacy and supporting evidence for its security profile."
How many centers are overseeing this clinical trial?
"At the moment, this medical trial is being conducted in 443 sites across the United States. These include Jasper, Phoenix and La Jolla, with a variety of other locations available to choose from. Choosing an institution close to you can help reduce any associated travelling costs that may be incurred when enrolling in the study."
Are there still openings available for the trial participants?
"Per information hosted on clinicaltrials.gov, this experiment is not presently enrolling participants. The trial was first published on August 16th 2023 and last edited a day later; however, there are currently 434 alternative trials actively seeking volunteers."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends